{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T18:10:00Z","timestamp":1770919800205,"version":"3.50.1"},"reference-count":147,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T00:00:00Z","timestamp":1733097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T00:00:00Z","timestamp":1733097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Metastasis Rev"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s10555-024-10234-2","type":"journal-article","created":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T15:30:25Z","timestamp":1733153425000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Ribosomal rodeo: wrangling translational machinery in gynecologic tumors"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3139-5901","authenticated-orcid":false,"given":"Kamil","family":"Filipek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1738-9767","authenticated-orcid":false,"given":"Marianna","family":"Penzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,2]]},"reference":[{"issue":"4","key":"10234_CR1","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.cell.2009.01.042","volume":"136","author":"N Sonenberg","year":"2009","unstructured":"Sonenberg, N., & Hinnebusch, A. G. (2009). Regulation of translation initiation in eukaryotes: Mechanisms and biological targets. Cell, 136(4), 731\u2013745. https:\/\/doi.org\/10.1016\/j.cell.2009.01.042","journal-title":"Cell"},{"key":"10234_CR2","doi-asserted-by":"publisher","unstructured":"Ben-Shem, A., Garreau de Loubresse, N., Melnikov, S., Jenner, L., Yusupova, G., & Yusupov, M. (2011). The structure of the eukaryotic ribosome at 3.0 \u00c5 resolution. Science, 334(6062), 1524\u20131529. https:\/\/doi.org\/10.1126\/science.1212642","DOI":"10.1126\/science.1212642"},{"issue":"8","key":"10234_CR3","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.tibs.2017.05.005","volume":"42","author":"D Kressler","year":"2017","unstructured":"Kressler, D., Hurt, E., & Ba\u00dfler, J. (2017). A puzzle of life: Crafting ribosomal subunits. Trends in Biochemical Sciences, 42(8), 640\u2013654. https:\/\/doi.org\/10.1016\/j.tibs.2017.05.005","journal-title":"Trends in Biochemical Sciences"},{"key":"10234_CR4","doi-asserted-by":"publisher","unstructured":"Liljas, A. and Ehrenberg, M. 2013. Structural aspects of protein synthesis. 2nd edition. World Scientific, Singapore.\u00a0https:\/\/doi.org\/10.1142\/7793","DOI":"10.1142\/7793"},{"issue":"1","key":"10234_CR5","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.cell.2014.03.007","volume":"157","author":"S Wolff","year":"2014","unstructured":"Wolff, S., Weissman, J. S., & Dillin, A. (2014). Differential scales of protein quality control. Cell, 157(1), 52\u201364. https:\/\/doi.org\/10.1016\/j.cell.2014.03.007","journal-title":"Cell"},{"issue":"8","key":"10234_CR6","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.3390\/cells10081948","volume":"10","author":"M Jaafar","year":"2021","unstructured":"Jaafar, M., Paraqindes, H., Gabut, M., Diaz, J.-J., Marcel, V., & Durand, S. (2021). 2\u2032O-ribose methylation of ribosomal RNAs: Natural diversity in living organisms, biological processes, and diseases. Cells, 10(8), 1948. https:\/\/doi.org\/10.3390\/cells10081948","journal-title":"Cells"},{"issue":"4","key":"10234_CR7","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrd4505","volume":"14","author":"M Bhat","year":"2015","unstructured":"Bhat, M., Robichaud, N., Hulea, L., Sonenberg, N., Pelletier, J., & Topisirovic, I. (2015). Targeting the translation machinery in cancer. Nature Reviews Drug Discovery, 14(4), 261\u2013278. https:\/\/doi.org\/10.1038\/nrd4505","journal-title":"Nature Reviews Drug Discovery"},{"issue":"7","key":"10234_CR8","doi-asserted-by":"publisher","first-page":"a032896","DOI":"10.1101\/cshperspect.a032896","volume":"11","author":"N Robichaud","year":"2019","unstructured":"Robichaud, N., Sonenberg, N., Ruggero, D., & Schneider, R. J. (2019). Translational control in cancer. Cold Spring Harbor Perspectives in Biology, 11(7). https:\/\/doi.org\/10.1101\/cshperspect.a032896","journal-title":"Cold Spring Harbor Perspectives in Biology"},{"issue":"3","key":"10234_CR9","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/BF01756140","volume":"33","author":"LS Massad","year":"1991","unstructured":"Massad, L. S., Mutch, D. G., Kao, M. S., Powell, C. B., & Collins, J. L. (1991). Inhibition of protein synthesis enhances the lytic effects of tumor necrosis factor \u03b1 and interferon \u03b3 in cell lines derived from gynecological malignancies. Cancer Immunology, Immunotherapy\u202f: CII, 33(3), 183. https:\/\/doi.org\/10.1007\/BF01756140","journal-title":"Cancer Immunology, Immunotherapy : CII"},{"issue":"5A","key":"10234_CR10","first-page":"1871","volume":"14","author":"T Lang","year":"1994","unstructured":"Lang, T., Daxenbichler, G., & Marth, C. (1994). Effects of cytostatic agents on the expression of epidermal growth factor receptor in ovarian cancer cells. Anticancer research, 14(5A), 1871\u20131874.","journal-title":"Anticancer research"},{"issue":"2","key":"10234_CR11","doi-asserted-by":"publisher","first-page":"221","DOI":"10.3390\/medicina59020221","volume":"59","author":"M Schubert","year":"2023","unstructured":"Schubert, M., Mettler, L., Deenadayal Tolani, A., & Alkatout, I. (2023). Fertility preservation in endometrial cancer\u2014Treatment and molecular aspects. Medicina, 59(2), 221. https:\/\/doi.org\/10.3390\/medicina59020221","journal-title":"Medicina"},{"key":"10234_CR12","doi-asserted-by":"publisher","unstructured":"Berek, J. S., Matias\u2010Guiu, X., Creutzberg, C., Fotopoulou, C., Gaffney, D., Kehoe, S., \u2026 Concin, N. (2023). FIGO staging of endometrial cancer: 2023. International Journal of Gynecology & Obstetrics, 162(2), 383\u2013394. https:\/\/doi.org\/10.1002\/ijgo.14923","DOI":"10.1002\/ijgo.14923"},{"issue":"9","key":"10234_CR13","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.3390\/cancers12092407","volume":"12","author":"T D\u00f6rk","year":"2020","unstructured":"D\u00f6rk, T., Hillemanns, P., Tempfer, C., Breu, J., & Fleisch, M. C. (2020). Genetic susceptibility to endometrial cancer: Risk factors and clinical management. Cancers, 12(9), 2407. https:\/\/doi.org\/10.3390\/cancers12092407","journal-title":"Cancers"},{"key":"10234_CR14","doi-asserted-by":"publisher","unstructured":"Viswanathan, A. N., Feskanich, D., De Vivo, I., Hunter, D. J., Barbieri, R. L., Rosner, B., \u2026 Hankinson, S. E. (2005). Smoking and the risk of endometrial cancer: Results from the Nurses\u2019 Health Study. International Journal of Cancer, 114(6), 996\u20131001. https:\/\/doi.org\/10.1002\/ijc.20821","DOI":"10.1002\/ijc.20821"},{"issue":"23","key":"10234_CR15","doi-asserted-by":"publisher","first-page":"10293","DOI":"10.7314\/APJCP.2014.15.23.10293","volume":"15","author":"K-T Chu","year":"2015","unstructured":"Chu, K.-T., Song, Y., & Zhou, J.-H. (2015). No effect of energy intake overall on risk of endometrial cancers: A meta-analysis. Asian Pacific Journal of Cancer Prevention, 15(23), 10293\u201310298. https:\/\/doi.org\/10.7314\/APJCP.2014.15.23.10293","journal-title":"Asian Pacific Journal of Cancer Prevention"},{"key":"10234_CR16","doi-asserted-by":"publisher","unstructured":"Verbakel, J. Y., Heremans, R., Wynants, L., Epstein, E., De Cock, B., Pascual, M. A., \u2026 Van den Bosch, T. (2022). Risk assessment for endometrial cancer in women with abnormal vaginal bleeding: Results from the prospective IETA\u20101 cohort study. International Journal of Gynecology & Obstetrics, 159(1), 103\u2013110. https:\/\/doi.org\/10.1002\/ijgo.14097","DOI":"10.1002\/ijgo.14097"},{"key":"10234_CR17","doi-asserted-by":"publisher","unstructured":"Zhao, M., Zhang, M.-J., He, L.-J., Zuo, C.-M., Ding, S.-R., Golden, A. R., & Cai, L. (2023). Health-related quality of life with cervical cancer and precancer: A cross-sectional study in Yunnan Province, China. Clinical and Experimental Obstetrics & Gynecology, 50(8), 161. https:\/\/doi.org\/10.31083\/j.ceog5008161","DOI":"10.31083\/j.ceog5008161"},{"key":"10234_CR18","doi-asserted-by":"publisher","unstructured":"Wang, J., & Chen, L. (2019). The role of miRNAs in the invasion and metastasis of cervical cancer. Bioscience Reports, 39(3). https:\/\/doi.org\/10.1042\/BSR20181377","DOI":"10.1042\/BSR20181377"},{"key":"10234_CR19","doi-asserted-by":"publisher","unstructured":"Xing, B., Guo, J., Sheng, Y., Wu, G., & Zhao, Y. (2021). human papillomavirus-negative cervical cancer: A comprehensive review. Frontiers in Oncology, 10. https:\/\/doi.org\/10.3389\/fonc.2020.606335","DOI":"10.3389\/fonc.2020.606335"},{"issue":"3","key":"10234_CR20","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1002\/ijc.22527","volume":"121","author":"JS Smith","year":"2007","unstructured":"Smith, J. S., Lindsay, L., Hoots, B., Keys, J., Franceschi, S., Winer, R., & Clifford, G. M. (2007). Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: A meta-analysis update. International Journal of Cancer, 121(3), 621\u2013632. https:\/\/doi.org\/10.1002\/ijc.22527","journal-title":"International Journal of Cancer"},{"key":"10234_CR21","doi-asserted-by":"publisher","unstructured":"Torre, L. A., Trabert, B., DeSantis, C. E., Miller, K. D., Samimi, G., Runowicz, C. D., \u2026 Siegel, R. L. (2018). Ovarian cancer statistics, 2018. CA: A Cancer Journal for Clinicians, 68(4), 284\u2013296. https:\/\/doi.org\/10.3322\/caac.21456","DOI":"10.3322\/caac.21456"},{"issue":"11","key":"10234_CR22","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/nrc2946","volume":"10","author":"DDL Bowtell","year":"2010","unstructured":"Bowtell, D. D. L. (2010). The genesis and evolution of high-grade serous ovarian cancer. Nature Reviews Cancer, 10(11), 803\u2013808. https:\/\/doi.org\/10.1038\/nrc2946","journal-title":"Nature Reviews Cancer"},{"key":"10234_CR23","doi-asserted-by":"publisher","unstructured":"Siegel, R. L., Miller, K. D., & Jemal, A. (2018). Cancer statistics, 2018. CA: A Cancer Journal for Clinicians, 68(1), 7\u201330. https:\/\/doi.org\/10.3322\/caac.21442","DOI":"10.3322\/caac.21442"},{"key":"10234_CR24","doi-asserted-by":"publisher","unstructured":"Huang, J., Chan, W. C., Ngai, C. H., Lok, V., Zhang, L., Lucero-Prisno, D. E., \u2026 Wong, M. C. S. (2022). Worldwide burden, risk factors, and temporal trends of ovarian cancer: A global study. Cancers, 14(9), 2230. https:\/\/doi.org\/10.3390\/cancers14092230","DOI":"10.3390\/cancers14092230"},{"key":"10234_CR25","doi-asserted-by":"publisher","first-page":"287","DOI":"10.2147\/IJWH.S197604","volume":"11","author":"Z Momenimovahed","year":"2019","unstructured":"Momenimovahed, Z., Tiznobaik, A., Taheri, S., & Salehiniya, H. (2019). Ovarian cancer in the world: Epidemiology and risk factors. International Journal of Women\u2019s Health, 11, 287\u2013299. https:\/\/doi.org\/10.2147\/IJWH.S197604","journal-title":"International Journal of Women\u2019s Health"},{"issue":"6","key":"10234_CR26","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.hoc.2018.07.010","volume":"32","author":"B Orr","year":"2018","unstructured":"Orr, B., & Edwards, R. P. (2018). Diagnosis and treatment of ovarian cancer. Hematology\/Oncology Clinics of North America, 32(6), 943\u2013964. https:\/\/doi.org\/10.1016\/j.hoc.2018.07.010","journal-title":"Hematology\/Oncology Clinics of North America"},{"key":"10234_CR27","doi-asserted-by":"publisher","unstructured":"McCluggage, W. G., Singh, N., & Gilks, C. B. (2022). Key changes to the World Health Organization (WHO) classification of female genital tumours introduced in the 5th edition (2020). Histopathology, 80(5), 762\u2013778. https:\/\/doi.org\/10.1111\/his.14609","DOI":"10.1111\/his.14609"},{"issue":"S1","key":"10234_CR28","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/ijgo.13881","volume":"155","author":"AB Olawaiye","year":"2021","unstructured":"Olawaiye, A. B., Cuello, M. A., & Rogers, L. J. (2021). Cancer of the vulva: 2021 update. International Journal of Gynecology & Obstetrics, 155(S1), 7\u201318. https:\/\/doi.org\/10.1002\/ijgo.13881","journal-title":"International Journal of Gynecology & Obstetrics"},{"key":"10234_CR29","doi-asserted-by":"publisher","unstructured":"Avril, N., Gourtsoyianni, S., & Reznek, R. (2011). Gynecological cancers (pp. 171\u2013189). https:\/\/doi.org\/10.1007\/978-1-61779-062-1_10","DOI":"10.1007\/978-1-61779-062-1_10"},{"issue":"20","key":"10234_CR30","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1200\/JCO.2007.11.0932","volume":"25","author":"AN Fader","year":"2007","unstructured":"Fader, A. N., & Rose, P. G. (2007). Role of surgery in ovarian carcinoma. Journal of Clinical Oncology, 25(20), 2873\u20132883. https:\/\/doi.org\/10.1200\/JCO.2007.11.0932","journal-title":"Journal of Clinical Oncology"},{"key":"10234_CR31","doi-asserted-by":"publisher","unstructured":"Chargari, C., Peignaux, K., Escande, A., Renard, S., Lafond, C., Petit, A., \u2026 Haie-M\u00e9der, C. (2022). Radiotherapy of cervical cancer. Cancer\/Radioth\u00e9rapie, 26(1\u20132), 298\u2013308. https:\/\/doi.org\/10.1016\/j.canrad.2021.11.009","DOI":"10.1016\/j.canrad.2021.11.009"},{"key":"10234_CR32","doi-asserted-by":"publisher","unstructured":"Bejar, F. G., Oaknin, A., Williamson, C., Mayadev, J., Peters, P. N., Secord, A. A., \u2026 Coffman, L. G. (2022). Novel therapies in gynecologic cancer. American Society of Clinical Oncology Educational Book, (42), 483\u2013499. https:\/\/doi.org\/10.1200\/EDBK_351294","DOI":"10.1200\/EDBK_351294"},{"issue":"10","key":"10234_CR33","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s11864-017-0504-y","volume":"18","author":"JB Pakish","year":"2017","unstructured":"Pakish, J. B., & Jazaeri, A. A. (2017). Immunotherapy in gynecologic cancers: Are we there yet? Current Treatment Options in Oncology, 18(10), 59. https:\/\/doi.org\/10.1007\/s11864-017-0504-y","journal-title":"Current Treatment Options in Oncology"},{"issue":"3","key":"10234_CR34","doi-asserted-by":"publisher","first-page":"759","DOI":"10.3390\/cancers14030759","volume":"14","author":"S Mitra","year":"2022","unstructured":"Mitra, S., Lami, M. S., Ghosh, A., Das, R., Tallei, T. E., & Fatimawali, \u2026 Emran, T. Bin. (2022). Hormonal therapy for gynecological cancers: How far has science progressed toward clinical applications? Cancers, 14(3), 759. https:\/\/doi.org\/10.3390\/cancers14030759","journal-title":"Cancers"},{"issue":"1","key":"10234_CR35","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13048-019-0503-7","volume":"12","author":"V Dochez","year":"2019","unstructured":"Dochez, V., Caillon, H., Vaucel, E., Dimet, J., Winer, N., & Ducarme, G. (2019). Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review. Journal of Ovarian Research, 12(1), 28. https:\/\/doi.org\/10.1186\/s13048-019-0503-7","journal-title":"Journal of Ovarian Research"},{"key":"10234_CR36","doi-asserted-by":"publisher","unstructured":"Wu, L., Shang, W., Zhao, H., Rong, G., Zhang, Y., Xu, T., \u2026 Wang, F. (2019). In silico screening of circulating microRNAs as potential biomarkers for the diagnosis of ovarian cancer. Disease Markers, 2019, 1\u201312. https:\/\/doi.org\/10.1155\/2019\/7541857","DOI":"10.1155\/2019\/7541857"},{"issue":"1","key":"10234_CR37","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3390\/cells8010055","volume":"8","author":"M Penzo","year":"2019","unstructured":"Penzo, M., Montanaro, L., Trer\u00e9, D., & Derenzini, M. (2019). The ribosome biogenesis\u2014Cancer connection. Cells, 8(1), 55. https:\/\/doi.org\/10.3390\/cells8010055","journal-title":"Cells"},{"issue":"1","key":"10234_CR38","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1042\/bj3120163","volume":"312","author":"F Buttgereit","year":"1995","unstructured":"Buttgereit, F., & Brand, M. D. (1995). A hierarchy of ATP-consuming processes in mammalian cells. Biochemical Journal, 312(1), 163\u2013167. https:\/\/doi.org\/10.1042\/bj3120163","journal-title":"Biochemical Journal"},{"issue":"6","key":"10234_CR39","doi-asserted-by":"publisher","first-page":"3572","DOI":"10.1074\/jbc.M206781200","volume":"278","author":"TA Nevins","year":"2003","unstructured":"Nevins, T. A., Harder, Z. M., Korneluk, R. G., & Hol\u010d\u0131\u0301k, M. (2003). Distinct regulation of internal ribosome entry site-mediated translation following cellular stress is mediated by apoptotic fragments of eIF4G translation initiation factor family members eIF4GI and p97\/DAP5\/NAT1. Journal of Biological Chemistry, 278(6), 3572\u20133579. https:\/\/doi.org\/10.1074\/jbc.M206781200","journal-title":"Journal of Biological Chemistry"},{"issue":"2","key":"10234_CR40","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1083\/jcb.200710215","volume":"181","author":"F Ram\u00edrez-Valle","year":"2008","unstructured":"Ram\u00edrez-Valle, F., Braunstein, S., Zavadil, J., Formenti, S. C., & Schneider, R. J. (2008). eIF4GI links nutrient sensing by mTOR to cell proliferation and inhibition of autophagy. The Journal of cell biology, 181(2), 293\u2013307. https:\/\/doi.org\/10.1083\/jcb.200710215","journal-title":"The Journal of cell biology"},{"key":"10234_CR41","doi-asserted-by":"publisher","unstructured":"Jaiswal, P. K., Koul, S., Palanisamy, N., & Koul, H. K. (2019). Eukaryotic Translation Initiation Factor 4 Gamma 1 (EIF4G1): A target for cancer therapeutic intervention? Cancer Cell International, 19(1). https:\/\/doi.org\/10.1186\/s12935-019-0947-2","DOI":"10.1186\/s12935-019-0947-2"},{"key":"10234_CR42","doi-asserted-by":"publisher","unstructured":"Meril, S., Muhlbauer Avni, M., Lior, C., Bahlsen, M., Olender, T., Savidor, A., \u2026 Kimchi, A. (2024). Loss of EIF4G2 mediates aggressiveness in distinct human endometrial cancer subpopulations with poor survival outcome in patients. Oncogene. https:\/\/doi.org\/10.1038\/s41388-024-02981-x","DOI":"10.1038\/s41388-024-02981-x"},{"key":"10234_CR43","doi-asserted-by":"publisher","unstructured":"Smolle, M. A., Czapiewski, P., Lapi\u0144ska-Szumczyk, S., Majewska, H., Supernat, A., Zaczek, A., \u2026 Haybaeck, J. (2019). The prognostic significance of eukaryotic translation initiation factors (eIFs) in endometrial cancer. International Journal of Molecular Sciences, 20(24), 6169. https:\/\/doi.org\/10.3390\/ijms20246169","DOI":"10.3390\/ijms20246169"},{"key":"10234_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2020\/8984526","volume":"2020","author":"J Zheng","year":"2020","unstructured":"Zheng, J., Li, X., Zhang, C., & Zhang, Y. (2020). eIF4E Overexpression is associated with poor prognoses of ovarian cancer. Analytical Cellular Pathology, 2020, 1\u20137. https:\/\/doi.org\/10.1155\/2020\/8984526","journal-title":"Analytical Cellular Pathology"},{"issue":"6","key":"10234_CR45","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.3892\/ijo.2015.3201","volume":"47","author":"J Wan","year":"2015","unstructured":"Wan, J., Shi, F., Xu, Z., & Zhao, M. (2015). Knockdown of eIF4E suppresses cell proliferation, invasion and enhances cisplatin cytotoxicity in human ovarian cancer cells. International Journal of Oncology, 47(6), 2217\u20132225. https:\/\/doi.org\/10.3892\/ijo.2015.3201","journal-title":"International Journal of Oncology"},{"issue":"3","key":"10234_CR46","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.amjms.2019.05.013","volume":"358","author":"W Zhang","year":"2019","unstructured":"Zhang, W., Su, X., Li, S., Wang, Y., Wang, Q., & Zeng, H. (2019). Inhibiting MNK selectively targets cervical cancer via suppressing eIF4E-mediated \u03b2-catenin activation. The American Journal of the Medical Sciences, 358(3), 227\u2013234. https:\/\/doi.org\/10.1016\/j.amjms.2019.05.013","journal-title":"The American Journal of the Medical Sciences"},{"key":"10234_CR47","doi-asserted-by":"publisher","unstructured":"Wang, S., Pang, T., Gao, M., Kang, H., Ding, W., Sun, X., \u2026 Hu, X. (2013). HPV E6 induces eIF4E transcription to promote the proliferation and migration of cervical cancer. FEBS Letters, 587(6), 690\u2013697. https:\/\/doi.org\/10.1016\/j.febslet.2013.01.042","DOI":"10.1016\/j.febslet.2013.01.042"},{"key":"10234_CR48","doi-asserted-by":"publisher","unstructured":"Pang, T., Wang, S., Gao, M., Kang, H., Zhao, Y., Yao, Y., & Hu, X. (2015). HPV18 E7 induces the over transcription of eIF4E gene in cervical cancer. Iranian Journal of Basic Medical Sciences, 18(7), 684\u2013690. https:\/\/doi.org\/10.22038\/ijbms.2015.4651","DOI":"10.22038\/ijbms.2015.4651"},{"issue":"4","key":"10234_CR49","first-page":"1053","volume":"31","author":"ZM Shi","year":"2017","unstructured":"Shi, Z. M., Liu, Y. N., Fu, B., Shen, Y. F., & Li, L. M. (2017). Expression profile of eukaryotic translation initiation factor and matrix metalloproteinase 9 in endometrial cancer tissue. Journal of biological regulators and homeostatic agents, 31(4), 1053\u20131059.","journal-title":"Journal of biological regulators and homeostatic agents"},{"key":"10234_CR50","doi-asserted-by":"publisher","DOI":"10.3892\/or.2019.7437","author":"H Zhang","year":"2019","unstructured":"Zhang, H., Li, R., Li, Y., Yu, X., Sun, Q., Li, A., & Kong, Y. (2019). eIF4E-related miR-320a and miR-340-5p inhibit endometrial carcinoma cell metastatic capability by preventing TGF-\u03b21-induced epithelial-mesenchymal transition. Oncology Reports. https:\/\/doi.org\/10.3892\/or.2019.7437","journal-title":"Oncology Reports"},{"key":"10234_CR51","doi-asserted-by":"publisher","unstructured":"Lomnytska, M. I., Becker, S., Gemoll, T., Lundgren, C., Habermann, J., Olsson, A., \u2026 Auer, G. (2012). Impact of genomic stability on protein expression in endometrioid endometrial cancer. British Journal of Cancer, 106(7), 1297\u20131305. https:\/\/doi.org\/10.1038\/bjc.2012.67","DOI":"10.1038\/bjc.2012.67"},{"issue":"5","key":"10234_CR52","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1097\/IGC.0000000000000152","volume":"24","author":"S Liang","year":"2014","unstructured":"Liang, S., Zhou, Y., Chen, Y., Ke, G., Wen, H., & Wu, X. (2014). Decreased expression of EIF4A1 after preoperative brachytherapy predicts better tumor-specific survival in cervical cancer. International Journal of Gynecological Cancer, 24(5), 908\u2013915. https:\/\/doi.org\/10.1097\/IGC.0000000000000152","journal-title":"International Journal of Gynecological Cancer"},{"key":"10234_CR53","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.biopha.2018.03.071","volume":"102","author":"S Zhang","year":"2018","unstructured":"Zhang, S., Leng, T., Zhang, Q., Zhao, Q., Nie, X., & Yang, L. (2018). Sanguinarine inhibits epithelial ovarian cancer development via regulating long non-coding RNA CASC2-EIF4A3 axis and\/or inhibiting NF-\u03baB signaling or PI3K\/AKT\/mTOR pathway. Biomedicine and Pharmacotherapy, 102, 302\u2013308. https:\/\/doi.org\/10.1016\/j.biopha.2018.03.071","journal-title":"Biomedicine and Pharmacotherapy"},{"issue":"10","key":"10234_CR54","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/S1357-2725(97)00039-3","volume":"29","author":"BLJ Webb","year":"1997","unstructured":"Webb, B. L. J., & Proud, C. G. (1997). Eukaryotic initiation factor 2B (eIF2B). The International Journal of Biochemistry & Cell Biology, 29(10), 1127\u20131131. https:\/\/doi.org\/10.1016\/S1357-2725(97)00039-3","journal-title":"The International Journal of Biochemistry & Cell Biology"},{"key":"10234_CR55","doi-asserted-by":"publisher","unstructured":"Hou, L., Jiao, Y., Li, Y., Luo, Z., Zhang, X., Pan, G., \u2026 He, M. (2020). Low EIF2B5 expression predicts poor prognosis in ovarian cancer. Medicine (United States), 99(5), E18666. https:\/\/doi.org\/10.1097\/MD.0000000000018666","DOI":"10.1097\/MD.0000000000018666"},{"key":"10234_CR56","doi-asserted-by":"publisher","unstructured":"He, S. L., Chen, Y. L., Chen, Q. H., Tian, Q., & Yi, S. J. (2022). LncRNA KCNQ1OT1 promotes the metastasis of ovarian cancer by increasing the methylation of EIF2B5 promoter. Molecular Medicine, 28(1). https:\/\/doi.org\/10.1186\/s10020-022-00521-5","DOI":"10.1186\/s10020-022-00521-5"},{"issue":"10","key":"10234_CR57","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1093\/carcin\/bgac053","volume":"43","author":"SL He","year":"2022","unstructured":"He, S. L., Zhao, X., & Yi, S. J. (2022). CircAHNAK upregulates EIF2B5 expression to inhibit the progression of ovarian cancer by modulating the JAK2\/STAT3 signaling pathway. Carcinogenesis, 43(10), 941\u2013955. https:\/\/doi.org\/10.1093\/carcin\/bgac053","journal-title":"Carcinogenesis"},{"issue":"10","key":"10234_CR58","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.tibs.2006.08.005","volume":"31","author":"AG Hinnebusch","year":"2006","unstructured":"Hinnebusch, A. G. (2006). eIF3: A versatile scaffold for translation initiation complexes. Trends in Biochemical Sciences, 31(10), 553\u2013562. https:\/\/doi.org\/10.1016\/j.tibs.2006.08.005","journal-title":"Trends in Biochemical Sciences"},{"key":"10234_CR59","doi-asserted-by":"publisher","unstructured":"Wen, F., Wu, Z. Y., Nie, L., Zhang, Q. Z., Qin, Y. K., Zhou, Z. lun, \u2026 Zi, D. (2019). Eukaryotic initiation factor 3, subunit C silencing inhibits cell proliferation and promotes apoptosis in human ovarian cancer cells. Bioscience Reports, 39(8). https:\/\/doi.org\/10.1042\/BSR20191124","DOI":"10.1042\/BSR20191124"},{"key":"10234_CR60","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.biopha.2018.10.027","volume":"109","author":"L Wang","year":"2019","unstructured":"Wang, L., & Ouyang, L. (2019). Effects of EIF3B gene downregulation on apoptosis and proliferation of human ovarian cancer SKOV3 and HO-8910 cells. Biomedicine and Pharmacotherapy, 109, 831\u2013837. https:\/\/doi.org\/10.1016\/j.biopha.2018.10.027","journal-title":"Biomedicine and Pharmacotherapy"},{"key":"10234_CR61","doi-asserted-by":"publisher","unstructured":"Liu, T., Wei, Q., Jin, J., Luo, Q., Liu, Y., Yang, Y., \u2026 Yi, P. (2021). The m6A reader YTHDF1 promotes ovarian cancer progression via augmenting EIF3C translation. Nucleic Acids Research, 48(7), 3816\u20133831. https:\/\/doi.org\/10.1093\/NAR\/GKAA048","DOI":"10.1093\/NAR\/GKAA048"},{"key":"10234_CR62","doi-asserted-by":"publisher","unstructured":"Zhao, N., Guo, Y., He, Y., Chen, Y., & Xing, J. (2020). Eukaryotic initiation factor 3B is overexpressed and correlates with larger tumor size, advanced FIGO stage, and shorter overall survival in epithelial ovarian cancer patients. Journal of Clinical Laboratory Analysis, 34(8). https:\/\/doi.org\/10.1002\/jcla.23354","DOI":"10.1002\/jcla.23354"},{"key":"10234_CR63","doi-asserted-by":"publisher","unstructured":"Zhang, Y., Yu, J.-J., Tian, Y., Li, Z.-Z., Zhang, C.-Y., Zhang, S.-F., \u2026 Liu, Z.-Q. (2015). eIF3a improve cisplatin sensitivity in ovarian cancer by regulating XPC and p27Kip1 translation. Oncotarget, 6(28), 25441\u201325451. https:\/\/doi.org\/10.18632\/oncotarget.4555","DOI":"10.18632\/oncotarget.4555"},{"issue":"12","key":"10234_CR64","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1002\/2211-5463.12137","volume":"6","author":"Y Lin","year":"2016","unstructured":"Lin, Y., Zhang, R., & Zhang, P. (2016). Eukaryotic translation initiation factor 3 subunit D overexpression is associated with the occurrence and development of ovarian cancer. FEBS Open Bio, 6(12), 1201\u20131210. https:\/\/doi.org\/10.1002\/2211-5463.12137","journal-title":"FEBS Open Bio"},{"issue":"1","key":"10234_CR65","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1080\/21655979.2021.2024336","volume":"13","author":"Y Zhong","year":"2022","unstructured":"Zhong, Y., & Lan, J. (2022). Overexpression of Eukaryotic translation initiation factor 3D induces stem cell-like properties and metastasis in cervix cancer by activating FAK through inhibiting degradation of GRP78. Bioengineered, 13(1), 1952\u20131961. https:\/\/doi.org\/10.1080\/21655979.2021.2024336","journal-title":"Bioengineered"},{"key":"10234_CR66","doi-asserted-by":"publisher","unstructured":"Liu, Q., Liu, J., Zheng, D., Zhang, R., Xiang, Y., Xu, F., \u2026 Qin, J. (2023). EIF3D promoted cervical carcinoma through Warburg effect by interacting with GRP78. Journal of Obstetrics and Gynaecology, 43(1). https:\/\/doi.org\/10.1080\/01443615.2022.2130200","DOI":"10.1080\/01443615.2022.2130200"},{"issue":"2","key":"10234_CR67","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.molcel.2017.03.003","volume":"66","author":"AP Schuller","year":"2017","unstructured":"Schuller, A. P., Wu, C.C.-C., Dever, T. E., Buskirk, A. R., & Green, R. (2017). eIF5A functions globally in translation elongation and termination. Molecular Cell, 66(2), 194\u2013205.e5. https:\/\/doi.org\/10.1016\/j.molcel.2017.03.003","journal-title":"Molecular Cell"},{"key":"10234_CR68","doi-asserted-by":"publisher","unstructured":"Clement, P. M. J., Henderson, C. A., Jenkins, Z. A., Smit\u2010McBride, Z., Wolff, E. C., Hershey, J. W. B., \u2026 Johansson, H. E. (2003). Identification and characterization of eukaryotic initiation factor 5A\u20102. European Journal of Biochemistry, 270(21), 4254\u20134263. https:\/\/doi.org\/10.1046\/j.1432-1033.2003.03806.x","DOI":"10.1046\/j.1432-1033.2003.03806.x"},{"key":"10234_CR69","doi-asserted-by":"publisher","unstructured":"Zhao, G., Zhang, W., Dong, P., Watari, H., Guo, Y., Pfeffer, L. M., \u2026 Yue, J. (2021). EIF5A2 controls ovarian tumor growth and metastasis by promoting epithelial to mesenchymal transition via the TGF\u03b2 pathway. Cell and Bioscience, 11(1). https:\/\/doi.org\/10.1186\/s13578-021-00578-5","DOI":"10.1186\/s13578-021-00578-5"},{"key":"10234_CR70","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.biopha.2018.02.016","volume":"100","author":"J Zhang","year":"2018","unstructured":"Zhang, J., Li, X., Liu, X., Tian, F., Zeng, W., Xi, X., & Lin, Y. (2018). EIF5A1 promotes epithelial ovarian cancer proliferation and progression. Biomedicine and Pharmacotherapy, 100, 168\u2013175. https:\/\/doi.org\/10.1016\/j.biopha.2018.02.016","journal-title":"Biomedicine and Pharmacotherapy"},{"key":"10234_CR71","doi-asserted-by":"publisher","unstructured":"Yang, S. S., Gao, Y., Wang, D. Y., Xia, B. R., Liu, Y. D., Qin, Y., \u2026 Zhang, Y. Y. (2016). Overexpression of eukaryotic initiation factor 5A2 (EIF5A2) is associated with cancer progression and poor prognosis in patients with early-stage cervical cancer. Histopathology, 69(2), 276\u2013287. https:\/\/doi.org\/10.1111\/his.12933","DOI":"10.1111\/his.12933"},{"key":"10234_CR72","doi-asserted-by":"publisher","unstructured":"Yang, G. F., Xie, D., Liu, J. H., Luo, J. H., Li, L. J., Hua, W. F., \u2026 Guan, X. Y. (2009). Expression and amplification of eIF-5A2 in human epithelial ovarian tumors and overexpression of EIF-5A2 is a new independent predictor of outcome in patients with ovarian carcinoma. Gynecologic Oncology, 112(2), 314\u2013318. https:\/\/doi.org\/10.1016\/j.ygyno.2008.10.024","DOI":"10.1016\/j.ygyno.2008.10.024"},{"key":"10234_CR73","doi-asserted-by":"crossref","unstructured":"Guan, X.-Y., Fung, J. M.-W., Ma, N.-F., Lau, S.-H., Tai, L.-S., Xie, D., \u2026 Sham, J. S. T. (2004). Oncogenic role of eIF-5A2 in the development of ovarian cancer. CANCER RESEARCH (Vol. 64). Retrieved from http:\/\/aacrjournals.org\/cancerres\/article-pdf\/64\/12\/4197\/2515441\/zch01204004197.pdf","DOI":"10.1158\/0008-5472.CAN-03-3747"},{"issue":"5","key":"10234_CR74","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1177\/1533034616666722","volume":"16","author":"X Liu","year":"2017","unstructured":"Liu, X., Chen, D., Liu, J., Chu, Z., & Liu, D. (2017). Blocking modification of eukaryotic initiation 5A2 antagonizes cervical carcinoma via inhibition of RhoA\/ROCK signal transduction pathway. Technology in Cancer Research and Treatment, 16(5), 630\u2013638. https:\/\/doi.org\/10.1177\/1533034616666722","journal-title":"Technology in Cancer Research and Treatment"},{"issue":"6966","key":"10234_CR75","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/nature02160","volume":"426","author":"M Ceci","year":"2003","unstructured":"Ceci, M., Gaviraghi, C., Gorrini, C., Sala, L. A., Offenh\u00e4user, N., Carlo Marchisio, P., & Biffo, S. (2003). Release of eIF6 (p27BBP) from the 60S subunit allows 80S ribosome assembly. Nature, 426(6966), 579\u2013584. https:\/\/doi.org\/10.1038\/nature02160","journal-title":"Nature"},{"key":"10234_CR76","doi-asserted-by":"publisher","unstructured":"Flavin, R. J., Smyth, P. C., Finn, S. P., Laios, A., O\u2019Toole, S. A., Barrett, C., \u2026 O\u2019Leary, J. J. (2008). Altered eIF6 and Dicer expression is associated with clinicopathological features in ovarian serous carcinoma patients. Modern Pathology, 21(6), 676\u2013684. https:\/\/doi.org\/10.1038\/modpathol.2008.33","DOI":"10.1038\/modpathol.2008.33"},{"issue":"2","key":"10234_CR77","doi-asserted-by":"publisher","first-page":"e32047","DOI":"10.1371\/journal.pone.0032047","volume":"7","author":"D Benelli","year":"2012","unstructured":"Benelli, D., Cialfi, S., Pinzaglia, M., Talora, C., & Londei, P. (2012). The translation factor eIF6 is a notch-dependent regulator of cell migration and invasion. PLoS ONE, 7(2). https:\/\/doi.org\/10.1371\/journal.pone.0032047","journal-title":"PLoS ONE"},{"key":"10234_CR78","doi-asserted-by":"publisher","unstructured":"Pinzaglia, M., Montaldo, C., Polinari, D., Simone, M., La Teana, A., Tripodi, M., \u2026 Benelli, D. (2015). eIF6 over-expression increases the motility and invasiveness of cancer cells by modulating the expression of a critical subset of membrane-bound proteins. BMC Cancer, 15(1). https:\/\/doi.org\/10.1186\/s12885-015-1106-3","DOI":"10.1186\/s12885-015-1106-3"},{"issue":"1","key":"10234_CR79","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1146\/annurev.bi.60.070191.003441","volume":"60","author":"JWB Hershey","year":"1991","unstructured":"Hershey, J. W. B. (1991). Translational control in mammalian cells. Annual Review of Biochemistry, 60(1), 717\u2013755. https:\/\/doi.org\/10.1146\/annurev.bi.60.070191.003441","journal-title":"Annual Review of Biochemistry"},{"key":"10234_CR80","doi-asserted-by":"publisher","unstructured":"Abbas, W., Kumar, A., & Herbein, G. (2015). The eEF1A proteins: At the crossroads of oncogenesis, apoptosis, and viral infections. Frontiers in Oncology, 5. https:\/\/doi.org\/10.3389\/fonc.2015.00075","DOI":"10.3389\/fonc.2015.00075"},{"key":"10234_CR81","doi-asserted-by":"publisher","unstructured":"Tomlinson, V. A. L., Newbery, H. J., Bergmann, J. H., Boyd, J., Scott, D., Wray, N. R., \u2026 Abbott, C. M. (2007). Expression of eEF1A2 is associated with clear cell histology in ovarian carcinomas: Overexpression of the gene is not dependent on modifications at the EEF1A2 locus. British Journal of Cancer, 96(10), 1613\u20131620. https:\/\/doi.org\/10.1038\/sj.bjc.6603748","DOI":"10.1038\/sj.bjc.6603748"},{"issue":"3","key":"10234_CR82","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.ygyno.2007.11.019","volume":"108","author":"DE Pinke","year":"2008","unstructured":"Pinke, D. E., Kalloger, S. E., Francetic, T., Huntsman, D. G., & Lee, J. M. (2008). The prognostic significance of elongation factor eEF1A2 in ovarian cancer. Gynecologic Oncology, 108(3), 561\u2013568. https:\/\/doi.org\/10.1016\/j.ygyno.2007.11.019","journal-title":"Gynecologic Oncology"},{"key":"10234_CR83","doi-asserted-by":"publisher","unstructured":"Anand, N., Murthy, S., Amann, G., Wernick, M., Porter, L. A., Cukier, I. H., \u2026 Lee, J. M. (2002). Protein elongation factor EEF1A2 is a putative oncogene in ovarian cancer. Nature Genetics, 31(3), 301\u2013305. https:\/\/doi.org\/10.1038\/ng904","DOI":"10.1038\/ng904"},{"key":"10234_CR84","doi-asserted-by":"publisher","unstructured":"Sun, Y., Wong, N., Guan, Y., Salamanca, C. M., Jung, C. C., Lee, J. M., \u2026 Auersperg, N. (2008). The eukaryotic translation elongation factor eEF1A2 induces neoplastic properties and mediates tumorigenic effects of ZNF217 in precursor cells of human ovarian carcinomas. International Journal of Cancer, 123(8), 1761\u20131769. https:\/\/doi.org\/10.1002\/ijc.23708","DOI":"10.1002\/ijc.23708"},{"issue":"1","key":"10234_CR85","doi-asserted-by":"publisher","first-page":"e0191377","DOI":"10.1371\/journal.pone.0191377","volume":"13","author":"MdK Hassan","year":"2018","unstructured":"Hassan, Md. K., Kumar, D., Naik, M., & Dixit, M. (2018). The expression profile and prognostic significance of eukaryotic translation elongation factors in different cancers. PLoS ONE, 13(1). https:\/\/doi.org\/10.1371\/journal.pone.0191377","journal-title":"PLoS ONE"},{"key":"10234_CR86","doi-asserted-by":"publisher","unstructured":"Shi, N., Chen, X., Liu, R., Wang, D., Su, M., Wang, Q., \u2026 Gu, H. (2018). Eukaryotic elongation factors 2 promotes tumor cell proliferation and correlates with poor prognosis in ovarian cancer. Tissue and Cell, 53, 53\u201360. https:\/\/doi.org\/10.1016\/j.tice.2018.05.014","DOI":"10.1016\/j.tice.2018.05.014"},{"key":"10234_CR87","doi-asserted-by":"publisher","unstructured":"Dever, T. E., Dinman, J. D., & Green, R. (2018). Translation elongation and recoding in eukaryotes. Cold Spring Harbor perspectives in biology, 10(8). https:\/\/doi.org\/10.1101\/cshperspect.a032649","DOI":"10.1101\/cshperspect.a032649"},{"issue":"1","key":"10234_CR88","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1186\/s12885-022-09699-7","volume":"22","author":"Q Xu","year":"2022","unstructured":"Xu, Q., Liu, Y., Wang, S., Wang, J., Liu, L., Xu, Y., & Qin, Y. (2022). Interfering with the expression of EEF1D gene enhances the sensitivity of ovarian cancer cells to cisplatin. BMC Cancer, 22(1), 628. https:\/\/doi.org\/10.1186\/s12885-022-09699-7","journal-title":"BMC Cancer"},{"key":"10234_CR89","doi-asserted-by":"publisher","unstructured":"El Khoury, W., & Nasr, Z. (2021). Deregulation of ribosomal proteins in human cancers. Bioscience Reports, 41(12). https:\/\/doi.org\/10.1042\/BSR20211577","DOI":"10.1042\/BSR20211577"},{"issue":"1","key":"10234_CR90","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/s41392-021-00728-8","volume":"6","author":"J Kang","year":"2021","unstructured":"Kang, J., Brajanovski, N., Chan, K. T., Xuan, J., Pearson, R. B., & Sanij, E. (2021). Ribosomal proteins and human diseases: Molecular mechanisms and targeted therapy. Signal Transduction and Targeted Therapy, 6(1), 323. https:\/\/doi.org\/10.1038\/s41392-021-00728-8","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"13","key":"10234_CR91","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1158\/0008-5472.CAN-21-4087","volume":"82","author":"AR Elhamamsy","year":"2022","unstructured":"Elhamamsy, A. R., Metge, B. J., Alsheikh, H. A., Shevde, L. A., & Samant, R. S. (2022). Ribosome biogenesis: A central player in cancer metastasis and therapeutic resistance. Cancer Research, 82(13), 2344\u20132353. https:\/\/doi.org\/10.1158\/0008-5472.CAN-21-4087","journal-title":"Cancer Research"},{"issue":"15","key":"10234_CR92","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1038\/onc.2014.127","volume":"34","author":"J-J Li","year":"2015","unstructured":"Li, J.-J., & Xie, D. (2015). RACK1, a versatile hub in cancer. Oncogene, 34(15), 1890\u20131898. https:\/\/doi.org\/10.1038\/onc.2014.127","journal-title":"Oncogene"},{"issue":"4","key":"10234_CR93","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1074\/jbc.273.4.2379","volume":"273","author":"J Liliental","year":"1998","unstructured":"Liliental, J., & Chang, D. D. (1998). Rack1, a receptor for activated protein kinase C, interacts with integrin \u03b2 subunit. Journal of Biological Chemistry, 273(4), 2379\u20132383. https:\/\/doi.org\/10.1074\/jbc.273.4.2379","journal-title":"Journal of Biological Chemistry"},{"issue":"2","key":"10234_CR94","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1091\/mbc.e02-03-0142","volume":"14","author":"EA Cox","year":"2003","unstructured":"Cox, E. A., Bennin, D., Doan, A. T., O\u2019Toole, T., & Huttenlocher, A. (2003). RACK1 regulates integrin-mediated adhesion, protrusion, and chemotactic cell migration via its Src-binding site. Molecular Biology of the Cell, 14(2), 658\u2013669. https:\/\/doi.org\/10.1091\/mbc.e02-03-0142","journal-title":"Molecular Biology of the Cell"},{"issue":"1","key":"10234_CR95","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.cellsig.2006.06.011","volume":"19","author":"I Onishi","year":"2007","unstructured":"Onishi, I., Lin, P. J. C., Diering, G. H., Williams, W. P., & Numata, M. (2007). RACK1 associates with NHE5 in focal adhesions and positively regulates the transporter activity. Cellular Signalling, 19(1), 194\u2013203. https:\/\/doi.org\/10.1016\/j.cellsig.2006.06.011","journal-title":"Cellular Signalling"},{"key":"10234_CR96","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.25012","author":"D Yang","year":"2024","unstructured":"Yang, D., Lu, X., Zhang, X., Zhang, X., Zhu, L., & Liu, Q. (2024). RACK1 promotes the occurrence and progression of cervical carcinoma. Journal of Clinical Laboratory Analysis. https:\/\/doi.org\/10.1002\/jcla.25012","journal-title":"Journal of Clinical Laboratory Analysis"},{"key":"10234_CR97","doi-asserted-by":"publisher","unstructured":"Wu, H., Song, S., Yan, A., Guo, X., Chang, L., Xu, L., \u2026 Ruan, Y. (2020). RACK1 promotes the invasive activities and lymph node metastasis of cervical cancer via galectin-1. Cancer Letters, 469, 287\u2013300. https:\/\/doi.org\/10.1016\/j.canlet.2019.11.002","DOI":"10.1016\/j.canlet.2019.11.002"},{"key":"10234_CR98","doi-asserted-by":"publisher","unstructured":"Liao, S., Xiao, S., Chen, H., Zhang, M., Chen, Z., Long, Y., \u2026 Zhou, Y. (2017). The receptor for activated protein kinase C promotes cell growth, invasion and migration in cervical cancer. International Journal of Oncology, 51(5), 1497\u20131507. https:\/\/doi.org\/10.3892\/ijo.2017.4137","DOI":"10.3892\/ijo.2017.4137"},{"key":"10234_CR99","doi-asserted-by":"publisher","unstructured":"Pi, Y., Feng, Q., Sun, F., Wang, Z., Zhao, Y., Chen, D., \u2026 Lou, G. (2023). Loss of SMURF2 expression enhances RACK1 stability and promotes ovarian cancer progression. Cell Death and Differentiation, 30(11), 2382\u20132392. https:\/\/doi.org\/10.1038\/s41418-023-01226-w","DOI":"10.1038\/s41418-023-01226-w"},{"key":"10234_CR100","doi-asserted-by":"publisher","unstructured":"Challa, S., Nandu, T., Kim, H. B., Gong, A., Renshaw, C. W., Li, W.-C., \u2026 Kraus, W. L. (2023). A PARP14\/TARG1-regulated RACK1 MARylation cycle drives stress granule dynamics in ovarian cancer cells. bioRxiv\u202f: the preprint server for biology. https:\/\/doi.org\/10.1101\/2023.10.13.562273","DOI":"10.1101\/2023.10.13.562273"},{"issue":"1","key":"10234_CR101","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1186\/s12935-020-01435-0","volume":"20","author":"J Wang","year":"2020","unstructured":"Wang, J., & Chen, S. (2020). RACK1 promotes miR-302b\/c\/d-3p expression and inhibits CCNO expression to induce cell apoptosis in cervical squamous cell carcinoma. Cancer Cell International, 20(1), 385. https:\/\/doi.org\/10.1186\/s12935-020-01435-0","journal-title":"Cancer Cell International"},{"issue":"1","key":"10234_CR102","doi-asserted-by":"publisher","first-page":"e999576","DOI":"10.1080\/21690731.2014.999576","volume":"3","author":"A Ghosh","year":"2015","unstructured":"Ghosh, A., & Komar, A. A. (2015). Eukaryote-specific extensions in ribosomal proteins of the small subunit: Structure and function. Translation, 3(1). https:\/\/doi.org\/10.1080\/21690731.2014.999576","journal-title":"Translation"},{"issue":"4","key":"10234_CR103","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/ni.2007","volume":"12","author":"F Wan","year":"2011","unstructured":"Wan, F., Weaver, A., Gao, X., Bern, M., Hardwidge, P. R., & Lenardo, M. J. (2011). IKK\u03b2 phosphorylation regulates RPS3 nuclear translocation and NF-\u03baB function during infection with Escherichia coli strain O157: H7. Nature Immunology, 12(4), 335\u2013343. https:\/\/doi.org\/10.1038\/ni.2007","journal-title":"Nature Immunology"},{"issue":"5","key":"10234_CR104","doi-asserted-by":"publisher","first-page":"2965","DOI":"10.1074\/jbc.M112.385989","volume":"288","author":"HJ Yang","year":"2013","unstructured":"Yang, H. J., Youn, H., Seong, K. M., Jin, Y.-W., Kim, J., & Youn, B. (2013). Phosphorylation of ribosomal protein S3 and antiapoptotic TRAF2 protein mediates radioresistance in non-small cell lung cancer cells. Journal of Biological Chemistry, 288(5), 2965\u20132975. https:\/\/doi.org\/10.1074\/jbc.M112.385989","journal-title":"Journal of Biological Chemistry"},{"key":"10234_CR105","doi-asserted-by":"publisher","unstructured":"Chen, L., Gao, W., Sha, C., Yang, M., Lin, L., Li, T., \u2026 Zhu, X. (2022). SIAH1-mediated RPS3 ubiquitination contributes to chemosensitivity in epithelial ovarian cancer. Aging, 14(15), 6202\u20136226. https:\/\/doi.org\/10.18632\/aging.204211","DOI":"10.18632\/aging.204211"},{"key":"10234_CR106","doi-asserted-by":"publisher","unstructured":"Tsofack, S. P., Meunier, L., Sanchez, L., Madore, J., Provencher, D., Mes-Masson, A. M., & Lebel, M. (2013). Low expression of the X-linked ribosomal protein S4 in human serous epithelial ovarian cancer is associated with a poor prognosis. BMC Cancer, 13. https:\/\/doi.org\/10.1186\/1471-2407-13-303","DOI":"10.1186\/1471-2407-13-303"},{"key":"10234_CR107","doi-asserted-by":"publisher","unstructured":"Yang, X., Xu, L., Yang, Y. E., Xiong, C., Yu, J., Wang, Y., & Lin, Y. (2020). Knockdown of ribosomal protein S6 suppresses proliferation, migration, and invasion in epithelial ovarian cancer. Journal of Ovarian Research, 13(1). https:\/\/doi.org\/10.1186\/s13048-020-00707-7","DOI":"10.1186\/s13048-020-00707-7"},{"key":"10234_CR108","doi-asserted-by":"publisher","unstructured":"Meyuhas, O. (2008). Chapter 1 Physiological roles of ribosomal protein S6: one of its kind (pp. 1\u201337). https:\/\/doi.org\/10.1016\/S1937-6448(08)00801-0","DOI":"10.1016\/S1937-6448(08)00801-0"},{"issue":"11","key":"10234_CR109","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1038\/modpathol.2013.85","volume":"26","author":"AP Pinto","year":"2013","unstructured":"Pinto, A. P., Degen, M., Barron, P., Crum, C. P., & Rheinwald, J. G. (2013). Phosphorylated S6 as an immunohistochemical biomarker of vulvar intraepithelial neoplasia. Modern Pathology, 26(11), 1498\u20131507. https:\/\/doi.org\/10.1038\/modpathol.2013.85","journal-title":"Modern Pathology"},{"key":"10234_CR110","doi-asserted-by":"publisher","unstructured":"Challa, S., Khulpateea, B. R., Nandu, T., Camacho, C. V., Ryu, K. W., Chen, H., \u2026 Kraus, W. L. (2021). Ribosome ADP-ribosylation inhibits translation and maintains proteostasis in cancers. Cell, 184(17), 4531\u20134546.e26. https:\/\/doi.org\/10.1016\/j.cell.2021.07.005","DOI":"10.1016\/j.cell.2021.07.005"},{"key":"10234_CR111","doi-asserted-by":"publisher","unstructured":"Wang, Z., Hou, J., Lu, L., Qi, Z., Sun, J., Gao, W., \u2026 Yang, G. (2013). Small ribosomal protein subunit S7 suppresses ovarian tumorigenesis through regulation of the PI3K\/AKT and MAPK pathways. PLoS ONE, 8(11). https:\/\/doi.org\/10.1371\/journal.pone.0079117","DOI":"10.1371\/journal.pone.0079117"},{"key":"10234_CR112","doi-asserted-by":"publisher","unstructured":"Lin, C. W., Lai, G. M., Chen, K. C., Lin, T. H., Fan, J. J., Hsu, R. L., \u2026 Cheng, C. H. (2015). RPS12 increases the invasiveness in cervical cancer activated by c-Myc and inhibited by the dietary flavonoids luteolin and quercetin. Journal of Functional Foods, 19, 236\u2013247. https:\/\/doi.org\/10.1016\/j.jff.2015.09.030","DOI":"10.1016\/j.jff.2015.09.030"},{"key":"10234_CR113","doi-asserted-by":"publisher","unstructured":"Wang, Q., Cai, Y., Fu, X., & Chen, L. (2021). High RPS27A expression predicts poor prognosis in patients with HPV type 16 cervical cancer. Frontiers in Oncology, 11. https:\/\/doi.org\/10.3389\/fonc.2021.752974","DOI":"10.3389\/fonc.2021.752974"},{"key":"10234_CR114","doi-asserted-by":"publisher","unstructured":"Shi, J., Zhang, L., Zhou, D., Zhang, J., Lin, Q., Guan, W., \u2026 Xu, G. (2018). Biological function of ribosomal protein L10 on cell behavior in human epithelial ovarian cancer. Journal of Cancer, 9(4), 745\u2013756. https:\/\/doi.org\/10.7150\/jca.21614","DOI":"10.7150\/jca.21614"},{"key":"10234_CR115","doi-asserted-by":"publisher","unstructured":"Wu, N., Wei, J., Wang, Y., Yan, J., Qin, Y., Tong, D., \u2026 Jin, Y. (2015). Ribosomal L22-like1 (RPL22L1) promotes ovarian cancer metastasis by inducing epithelial-to-mesenchymal transition. PLoS ONE, 10(11). https:\/\/doi.org\/10.1371\/journal.pone.0143659","DOI":"10.1371\/journal.pone.0143659"},{"issue":"3","key":"10234_CR116","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.cell.2004.07.011","volume":"118","author":"Y Kang","year":"2004","unstructured":"Kang, Y., & Massagu\u00e9, J. (2004). Epithelial-mesenchymal transitions. Cell, 118(3), 277\u2013279. https:\/\/doi.org\/10.1016\/j.cell.2004.07.011","journal-title":"Cell"},{"key":"10234_CR117","doi-asserted-by":"publisher","unstructured":"Kang, H., Choi, M. C., Kim, S., Jeong, J. Y., Kwon, A. Y., Kim, T. H., \u2026 An, H. J. (2021). Usp19 and rpl23 as candidate prognostic markers for advanced-stage high-grade serous ovarian carcinoma. Cancers, 13(16). https:\/\/doi.org\/10.3390\/cancers13163976","DOI":"10.3390\/cancers13163976"},{"key":"10234_CR118","doi-asserted-by":"publisher","unstructured":"Ming, C., Bai, X., Zhao, L., Yu, D., Wang, X., & Wu, Y. (2023). RPL24 as a potential prognostic biomarker for cervical cancer treated by Cisplatin and concurrent chemoradiotherapy. Frontiers in Oncology, 13. https:\/\/doi.org\/10.3389\/fonc.2023.1131803","DOI":"10.3389\/fonc.2023.1131803"},{"key":"10234_CR119","doi-asserted-by":"publisher","unstructured":"Zhu, Y., Ren, C., Jiang, D., Yang, L., Chen, Y., Li, F., \u2026 Zhang, Y. (2021). RPL34-AS1\u2013induced RPL34 inhibits cervical cancer cell tumorigenesis via the MDM2-P53 pathway. Cancer Science, 112(5), 1811\u20131821. https:\/\/doi.org\/10.1111\/cas.14874","DOI":"10.1111\/cas.14874"},{"key":"10234_CR120","doi-asserted-by":"publisher","unstructured":"Wu, H., Xia, L., Sun, L., Li, D., Liu, X., Song, H., \u2026 Feng, Q. (2024). RPL35A drives ovarian cancer progression by promoting the binding of YY1 to CTCF promoter. Journal of Cellular and Molecular Medicine, 28(6). https:\/\/doi.org\/10.1111\/jcmm.18115","DOI":"10.1111\/jcmm.18115"},{"issue":"9","key":"10234_CR121","doi-asserted-by":"publisher","first-page":"445","DOI":"10.5483\/BMBRep.2017.50.9.108","volume":"50","author":"S Oh","year":"2017","unstructured":"Oh, S., Oh, C., & Yoo, K. H. (2017). Functional roles of CTCF in breast cancer. BMB Reports, 50(9), 445\u2013453. https:\/\/doi.org\/10.5483\/BMBRep.2017.50.9.108","journal-title":"BMB Reports"},{"key":"10234_CR122","doi-asserted-by":"publisher","unstructured":"Sun, F., Wei, Y., Liu, Z., Jie, Q., Yang, X., Long, P., \u2026 Ma, Y. (2022). Acylglycerol kinase promotes ovarian cancer progression and regulates mitochondria function by interacting with ribosomal protein L39. Journal of Experimental and Clinical Cancer Research, 41(1). https:\/\/doi.org\/10.1186\/s13046-022-02448-5","DOI":"10.1186\/s13046-022-02448-5"},{"issue":"2","key":"10234_CR123","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.humpath.2010.04.020","volume":"42","author":"A Artero-Castro","year":"2011","unstructured":"Artero-Castro, A., Castellvi, J., Garc\u00eda, A., Hern\u00e1ndez, J., Cajal, S. R. Y., & Lleonart, M. E. (2011). Expression of the ribosomal proteins Rplp0, Rplp1, and Rplp2 in gynecologic tumors. Human Pathology, 42(2), 194\u2013203. https:\/\/doi.org\/10.1016\/j.humpath.2010.04.020","journal-title":"Human Pathology"},{"key":"10234_CR124","doi-asserted-by":"publisher","unstructured":"Xia, L., Yue, Y., Li, M., Zhang, Y. N., Zhao, L., Lu, W., \u2026 Xie, X. (2020). CNN3 acts as a potential oncogene in cervical cancer by affecting RPLP1 mRNA expression. Scientific Reports, 10(1). https:\/\/doi.org\/10.1038\/s41598-020-58947-y","DOI":"10.1038\/s41598-020-58947-y"},{"key":"10234_CR125","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.1017\/S0033583518000100","volume":"51","author":"A Liljas","year":"2018","unstructured":"Liljas, A., & Sanyal, S. (2018). The enigmatic ribosomal stalk. Quarterly Reviews of Biophysics, 51,. https:\/\/doi.org\/10.1017\/S0033583518000100","journal-title":"Quarterly Reviews of Biophysics"},{"key":"10234_CR126","doi-asserted-by":"publisher","unstructured":"Penzo, M., Montanaro, L., Trer\u00e9, D., & Derenzini, M. (2019, January 1). The ribosome biogenesis-cancer connection. Cells. MDPI. https:\/\/doi.org\/10.3390\/cells8010055","DOI":"10.3390\/cells8010055"},{"issue":"5","key":"10234_CR127","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/NRC.2016.27","volume":"16","author":"ML Truitt","year":"2016","unstructured":"Truitt, M. L., & Ruggero, D. (2016). New frontiers in translational control of the cancer genome. Nature reviews. Cancer, 16(5), 288\u2013304. https:\/\/doi.org\/10.1038\/NRC.2016.27","journal-title":"Nature reviews. Cancer"},{"issue":"6","key":"10234_CR128","doi-asserted-by":"publisher","first-page":"8327","DOI":"10.1002\/JCP.27722","volume":"234","author":"G Molavi","year":"2019","unstructured":"Molavi, G., Samadi, N., & Hosseingholi, E. Z. (2019). The roles of moonlight ribosomal proteins in the development of human cancers. Journal of cellular physiology, 234(6), 8327\u20138341. https:\/\/doi.org\/10.1002\/JCP.27722","journal-title":"Journal of cellular physiology"},{"key":"10234_CR129","doi-asserted-by":"publisher","unstructured":"Toden, S., Zumwalt, T. J., & Goel, A. (2021). Non-coding RNAs and potential therapeutic targeting in cancer. Biochimica et biophysica acta. Reviews on cancer, 1875(1). https:\/\/doi.org\/10.1016\/J.BBCAN.2020.188491","DOI":"10.1016\/J.BBCAN.2020.188491"},{"key":"10234_CR130","doi-asserted-by":"publisher","unstructured":"Panwar, V., Singh, A., Bhatt, M., Tonk, R. K., Azizov, S., Raza, A. S., \u2026 Garg, M. (2023). Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease. Signal Transduction and Targeted Therapy 2023 8:1, 8(1), 1\u201325. https:\/\/doi.org\/10.1038\/s41392-023-01608-z","DOI":"10.1038\/s41392-023-01608-z"},{"key":"10234_CR131","doi-asserted-by":"publisher","unstructured":"Rinne, N., Christie, E. L., Ardasheva, A., Kwok, C. H., Demchenko, N., Low, C., \u2026 Cunnea, P. (2021). Targeting the PI3K\/AKT\/mTOR pathway in epithelial ovarian cancer, therapeutic treatment options for platinum-resistant ovarian cancer. Cancer Drug Resist 2021;4:573\u201395., 4(3), 573\u2013595. https:\/\/doi.org\/10.20517\/CDR.2021.05","DOI":"10.20517\/CDR.2021.05"},{"issue":"5","key":"10234_CR132","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1021\/ACS.JMEDCHEM.0C01746\/ASSET\/IMAGES\/LARGE\/JM0C01746_0027.JPEG","volume":"64","author":"A Fan","year":"2021","unstructured":"Fan, A., & Sharp, P. P. (2021). Inhibitors of eukaryotic translational machinery as therapeutic agents. Journal of Medicinal Chemistry, 64(5), 2436\u20132465. https:\/\/doi.org\/10.1021\/ACS.JMEDCHEM.0C01746\/ASSET\/IMAGES\/LARGE\/JM0C01746_0027.JPEG","journal-title":"Journal of Medicinal Chemistry"},{"key":"10234_CR133","doi-asserted-by":"publisher","first-page":"105535","DOI":"10.1016\/J.PHRS.2021.105535","volume":"170","author":"LD Burgers","year":"2021","unstructured":"Burgers, L. D., & F\u00fcrst, R. (2021). Natural products as drugs and tools for influencing core processes of eukaryotic mRNA translation. Pharmacological Research, 170,. https:\/\/doi.org\/10.1016\/J.PHRS.2021.105535","journal-title":"Pharmacological Research"},{"key":"10234_CR134","doi-asserted-by":"publisher","unstructured":"Temaj, G., Chichiarelli, S., Eufemi, M., Altieri, F., Hadziselimovic, R., Farooqi, A. A., \u2026 Saso, L. (2022). Ribosome-directed therapies in cancer. Biomedicines, 10(9). https:\/\/doi.org\/10.3390\/BIOMEDICINES10092088","DOI":"10.3390\/BIOMEDICINES10092088"},{"key":"10234_CR135","doi-asserted-by":"publisher","unstructured":"Temaj, G., Chichiarelli, S., Telkoparan-Akillilar, P., Saha, S., Nuhii, N., Hadziselimovic, R., & Saso, L. (2024). P53: A key player in diverse cellular processes including nuclear stress and ribosome biogenesis, highlighting potential therapeutic compounds. Biochemical pharmacology, 226. https:\/\/doi.org\/10.1016\/J.BCP.2024.116332","DOI":"10.1016\/J.BCP.2024.116332"},{"key":"10234_CR136","doi-asserted-by":"publisher","unstructured":"Haddach, M., Schwaebe, M. K., Michaux, J., Nagasawa, J., O\u2019Brien, S. E., Whitten, J. P., \u2026 Ryckman, D. M. (2012). Discovery of CX-5461, the first direct and selective inhibitor of RNA polymerase I, for cancer therapeutics. ACS medicinal chemistry letters, 3(7), 602\u2013606. https:\/\/doi.org\/10.1021\/ML300110S","DOI":"10.1021\/ML300110S"},{"key":"10234_CR137","doi-asserted-by":"publisher","unstructured":"Bywater, M. J., Poortinga, G., Sanij, E., Hein, N., Peck, A., Cullinane, C., \u2026 Hannan, R. D. (2012). Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53. Cancer Cell, 22(1), 51\u201365. https:\/\/doi.org\/10.1016\/j.ccr.2012.05.019","DOI":"10.1016\/j.ccr.2012.05.019"},{"key":"10234_CR138","doi-asserted-by":"publisher","unstructured":"Sanij, E., Hannan, K. M., Xuan, J., Yan, S., Ahern, J. E., Trigos, A. S., \u2026 Pearson, R. B. (2020). CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer. Nature communications, 11(1). https:\/\/doi.org\/10.1038\/S41467-020-16393-4","DOI":"10.1038\/S41467-020-16393-4"},{"key":"10234_CR139","doi-asserted-by":"publisher","unstructured":"Yan, S., Frank, D., Son, J., Hannan, K. M., Hannan, R. D., Chan, K. T., \u2026 Sanij, E. (2017). The potential of targeting ribosome biogenesis in high-grade serous ovarian cancer. International journal of molecular sciences, 18(1). https:\/\/doi.org\/10.3390\/IJMS18010210","DOI":"10.3390\/IJMS18010210"},{"key":"10234_CR140","doi-asserted-by":"publisher","unstructured":"Pellegrino, S., Terrosu, S., Yusupova, G., & Yusupov, M. (2021). Inhibition of the eukaryotic 80S ribosome as a potential anticancer therapy: A structural perspective. Cancers, 13(17). https:\/\/doi.org\/10.3390\/CANCERS13174392\/S1","DOI":"10.3390\/CANCERS13174392\/S1"},{"issue":"S1","key":"10234_CR141","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1186\/1471-2105-11-S1-S41","volume":"11","author":"G Ciriello","year":"2010","unstructured":"Ciriello, G., Gallina, C., & Guerra, C. (2010). Analysis of interactions between ribosomal proteins and RNA structural motifs. BMC Bioinformatics, 11(S1), S41. https:\/\/doi.org\/10.1186\/1471-2105-11-S1-S41","journal-title":"BMC Bioinformatics"},{"key":"10234_CR142","doi-asserted-by":"publisher","unstructured":"Jouanneau, M., McClary, B., Reyes, J. C. P., Chen, R., Chen, Y., Plunkett, W., \u2026 Romo, D. (2016). Derivatization of agelastatin A leading to bioactive analogs and a trifunctional probe. Bioorganic & Medicinal Chemistry Letters, 26(8), 2092\u20132097. https:\/\/doi.org\/10.1016\/j.bmcl.2016.02.051","DOI":"10.1016\/j.bmcl.2016.02.051"},{"issue":"1","key":"10234_CR143","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s11101-020-09675-8","volume":"20","author":"L Cahl\u00edkov\u00e1","year":"2021","unstructured":"Cahl\u00edkov\u00e1, L., Kawano, I., \u0158ez\u00e1\u010dov\u00e1, M., Blunden, G., Hulcov\u00e1, D., & Havelek, R. (2021). The Amaryllidaceae alkaloids haemanthamine, haemanthidine and their semisynthetic derivatives as potential drugs. Phytochemistry Reviews, 20(1), 303\u2013323. https:\/\/doi.org\/10.1007\/s11101-020-09675-8","journal-title":"Phytochemistry Reviews"},{"key":"10234_CR144","doi-asserted-by":"publisher","unstructured":"Pellegrino, S., Meyer, M., Zorbas, C., Bouchta, S. A., Saraf, K., Pelly, S. C., \u2026 Yusupov, M. (2018). The Amaryllidaceae alkaloid haemanthamine binds the eukaryotic ribosome to repress cancer cell growth. Structure, 26(3), 416\u2013425.e4. https:\/\/doi.org\/10.1016\/J.STR.2018.01.009","DOI":"10.1016\/J.STR.2018.01.009"},{"key":"10234_CR145","doi-asserted-by":"publisher","unstructured":"Carter, K., Rameshwar, P., Ratajczak, M. Z., & Kakar, S. S. (2017). Verrucarin J inhibits ovarian cancer and targets cancer stem cells. Oncotarget, 8(54), 92743\u201392756. https:\/\/doi.org\/10.18632\/ONCOTARGET.21574","DOI":"10.18632\/ONCOTARGET.21574"},{"issue":"3","key":"10234_CR146","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1039\/C2NP00065B","volume":"29","author":"J Lee","year":"2012","unstructured":"Lee, J., Currano, J. N., Carroll, P. J., & Joulli\u00e9, M. M. (2012). Didemnins, tamandarins and related natural products. Natural Product Reports, 29(3), 404\u2013424. https:\/\/doi.org\/10.1039\/C2NP00065B","journal-title":"Natural Product Reports"},{"key":"10234_CR147","doi-asserted-by":"publisher","unstructured":"Kanis, M. J., Qiang, W., Pineda, M., Maniar, K. P., & Kim, J. J. (2018). A small molecule inhibitor of the perinucleolar compartment, ML246, attenuates growth and spread of ovarian cancer. Gynecologic oncology research and practice, 5(1). https:\/\/doi.org\/10.1186\/S40661-018-0064-2","DOI":"10.1186\/S40661-018-0064-2"}],"container-title":["Cancer and Metastasis Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-024-10234-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10555-024-10234-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-024-10234-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T03:05:25Z","timestamp":1743303925000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10555-024-10234-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,2]]},"references-count":147,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10234"],"URL":"https:\/\/doi.org\/10.1007\/s10555-024-10234-2","relation":{},"ISSN":["0167-7659","1573-7233"],"issn-type":[{"value":"0167-7659","type":"print"},{"value":"1573-7233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,2]]},"assertion":[{"value":"13 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13"}}